X
1. 94-52-0
2. 6-nitrobenzimidazole
3. 5-nitro-1h-benzo[d]imidazole
4. 5-nitro-1h-benzimidazole
5. 6-nitro-1h-benzimidazole
6. 1h-benzimidazole, 5-nitro-
7. 1h-benzimidazole, 6-nitro-
8. 5(6)-nitrobenzimidazole
9. 6-nitro-benzimidazole
10. 5-nitro-1h-1,3-benzodiazole
11. Benzimidazole, 5-nitro-
12. Benzimidazole, 6-nitro-
13. Nci-c01912
14. 5-nitro-1h-benzoimidazole
15. Mfcd00005604
16. A7v95ayt2t
17. Mls002637666
18. Chembl164921
19. Benzimidazole, 5(or 6)-nitro-
20. Nsc-3068
21. Nsc-58858
22. 89843-47-0
23. Dsstox_cid_965
24. Dsstox_rid_75893
25. Dsstox_gsid_20965
26. Wln: T56 Bm Dnj Hnw
27. Cas-94-52-0
28. Ccris 442
29. Hsdb 2864
30. Nsc 3068
31. Einecs 202-341-2
32. Nsc 58858
33. Unii-a7v95ayt2t
34. 6-nitro-1h-benzo[d]imidazole
35. Ai3-52609
36. 6-nitro-1h-1,3-benzodiazole
37. 4msa
38. 1h-benzimidazole,5-nitro-
39. 2zm
40. 5-nitrobenzoimidazol
41. 5-nitrobenzoimidazole
42. 5-nitro-benzimidazole
43. 4n9c
44. 5(6)-nitro-benzimidazole
45. 6-nitro-1h-benzoimidazole
46. 1h-benzimidazole,6-nitro-
47. Oprea1_525754
48. Oprea1_664147
49. Schembl271340
50. 5-nitro-1h-1,3-benzimidazole
51. Dtxsid8020965
52. Nsc3068
53. Hms3079a05
54. 5-nitrobenzimidazole [hsdb]
55. Bcp26862
56. Nsc58858
57. Zinc4693007
58. Tox21_201684
59. Tox21_302828
60. Bdbm50208881
61. Mfcd00040457
62. Stk299272
63. Akos000275609
64. Akos003790796
65. Akos015970456
66. Cs-w010848
67. S10799
68. Ncgc00091868-01
69. Ncgc00091868-02
70. Ncgc00091868-03
71. Ncgc00091868-04
72. Ncgc00091868-05
73. Ncgc00091868-06
74. Ncgc00256398-01
75. Ncgc00259233-01
76. Ac-11286
77. Am808099
78. As-46775
79. Smr001305771
80. Sy003312
81. Db-057506
82. Bb 0219456
83. Eu-0067493
84. Ft-0620702
85. N0152
86. 040b457
87. 2-[(4,6-dimethoxypyrimidin-2-yl)thio]benzoicacid
88. Ae-641/30196001
89. Sr-01000394488
90. Sr-01000394488-1
91. W-100194
92. Q27273738
93. F0020-1984
| Molecular Weight | 163.13 g/mol |
|---|---|
| Molecular Formula | C7H5N3O2 |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 0 |
| Exact Mass | 163.038176411 g/mol |
| Monoisotopic Mass | 163.038176411 g/mol |
| Topological Polar Surface Area | 74.5 Ų |
| Heavy Atom Count | 12 |
| Formal Charge | 0 |
| Complexity | 192 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
EXPTL USE: RADIOBIOLOGICAL AND PHARMACOKINETIC ASSAYS WERE PERFORMED TO DETERMINE THE POTENTIAL OF 2-NITROBENZIMIDAZOLE (NBI) AS HYPOXIC CELL RADIOSENSITIZING AGENT. ACUTE TOXIC SIGNS APPEARED IN C3H/HEJ MICE FOLLOWING IP INJECTION OF NBI @ 100 MG/KG. THESE WOULD BE PARTLY ATTRIBUTABLE TO THE STRESS CAUSED BY THE HIGH PH OF THE INJECTION VEHICLE. ... MAMMARY ADENOCARCINOMA TUMORS GROWN IN THE FLANKS OF THESE MICE EXHIBITED MAXIMUM NBI LEVELS @ 5 MIN POSTINJECTION. PEAK TUMOR RADIOSENSITIZATION OCCURRED IN THE INTERVAL BETWEEN 5 AND 10 MIN POSTINJECTION. THE ENHANCEMENT RATIO FOR TUMOR REGROWTH DELAY WAS 2.1 +/- 0.3 FOLLOWING 50 MG/KG INJECTED INTO MICE 5 MIN BEFORE IRRADIATION. FUNCTIONAL EVALUATION UP TO 40 DAYS AFTER TREATMENT REVEALED NO EVIDENCE OF NEUROLOGICAL DEFICIT.
WRIGHT J ET AL; RADIAT RES 95(1) 187 (1983)
Market Place
